Cardiac Monitors in Texas

AirStrip Technologies develops clinical surveillance and alarm management software that consolidates siloed clinical data from EMRs, bedside monitors, and medical devices into vendor-agnostic mobile and web applications. The platform provides real-time patient monitoring with embedded waveforms, automated protocol management, and visual decision support across ICU, Emergency, Obstetrics, Cardiology, and Rapid Response units. Core capabilities include multi-patient monitoring (up to 40 patients per screen), diagnostic-quality 12-lead ECG capture with STEMI notifications, maternal and fetal waveform monitoring with real-time visualization, and comprehensive alarm triage and analytics. The software features digitized peer-reviewed clinical protocols, alarm trend analysis and responsiveness metrics, and context-aware clinical linking. AirStrip integrates with diverse hospital infrastructure systems while maintaining HIPAA compliance and meeting ISO 27001 security standards. The platform supports telemetry optimization workflows, door-to-balloon time reduction for acute coronary syndromes, and multi-unit alarm management at scale. Named one of TIME's World's Top HealthTech Companies in 2025 with an "outstanding" rating.

Precision Monitoring LLC is a healthcare company founded in 2015, headquartered in Burleson, Texas, with an additional office in San Jose, California. The company specializes in noninvasive cardiac ambulatory monitoring and remote healthcare diagnostics. Precision Monitoring delivers advanced cardiac care solutions through FDA-cleared ambulatory ECG monitoring systems, complemented by remote diagnostics supported by certified cardiac technicians. The platform emphasizes lethal arrhythmia detection, cardiac arrhythmia analysis, and secure patient data reporting to physicians. The company collaborates with clinicians nationwide to provide user-friendly monitoring technology with extensive patient data analysis and quality assurance. Precision Monitoring also offers healthcare management tools and ECG analysis software designed to assist physicians in implementing effective cardiac care strategies. The company serves patients primarily across Texas and California, operates under federal healthcare contracts, and holds Better Business Bureau accreditation since March 2023.

Smart-ABI, developed by Hyperion Medical, is a cloud-based diagnostic solution specializing in Ankle Brachial Index (ABI) testing combined with Pulse Volume Recording (PVR) for the rapid, non-invasive diagnosis of Peripheral Artery Disease (PAD) and related vascular conditions. With over 25 years of medical device industry experience, the Smart-ABI platform delivers fast, simple, and accurate vascular assessments that integrate seamlessly into existing electronic medical record systems. The Smart-ABI Hub is a HIPAA-compliant software-as-a-service platform that enables mobile access, collaborative care between providers and specialists, and secure report transmission. The company's comprehensive vascular testing solutions—including the core Smart-ABI device and Smart-LEDA for combined ABI and sudomotor function assessment—are designed to improve early diagnosis of underdiagnosed PAD, reduce major cardiovascular and limb events, and support evidence-based clinical decision-making in diverse care settings.

Wellysis Corp. is a digital health company specializing in wearable ECG monitoring and remote cardiac surveillance solutions. The company manufactures and distributes the S-Patch line, a patch-type ECG device powered by Samsung Smart Health Processor, designed as a replacement for traditional Holter monitors. The S-Patch ecosystem comprises four integrated components: (1) S-Patch Wear—a lightweight, wearable biosignal collection device available in standard (Ex) and extended (ExL) formats; (2) S-Patch App—a mobile application for real-time data monitoring compatible with both iOS and Android; (3) S-Patch Physician Web—a cloud-based reading and analysis platform with comprehensive ECG report generation; and (4) S-Patch AI—algorithmic decision-support functionality integrated across the platform. The company also offers SDK and API interoperability solutions for healthcare system integration. Wellysis received FDA 510(k) clearance in September 2023 and has established partnerships with major healthcare institutions, including Samsung Electronics, Kangbuk Samsung Hospital, and clinical organizations in the US and India. The platform targets hospitals, clinics, cardiac monitoring centers, and telehealth service providers. Recent strategic partnerships include collaborations with Medicalgorithmics S.A. and HeartcoR Solutions, expanding distribution in clinical trial and remote monitoring markets. The company is headquartered in South Korea with active US market presence.